Results 61 to 70 of about 9,359 (237)
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
Diabetes, Metabolic Syndrome and Obesity, 2009 Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30 ...
Gregory E Peterson
doaj
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. [PDF]
PLoS ONE, 2016 BACKGROUND:Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear.
Arto Y Strandberg +5 more
doaj +1 more source
Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs
Advanced Healthcare Materials, Volume 15, Issue 5, 2 February 2026.Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner +8 more
wiley +1 more source
Insulin detemir in the treatment of type 1 and type 2 diabetes
Vascular Health and Risk Management, 2006 Jean-Christophe Philips, André ScheenDivision of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart-Tilman, University of Liège, Liège, Belgium Abstract: Insulin detemir is a soluble long-acting human ...
Jean-Christophe Philips +1 more
doaj
Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Сахарный диабет, 2017 Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin.
Lyudmila Alexandrovna Ruyatkina +1 more
doaj +1 more source
Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. [PDF]
PLoS ONE, 2018 BACKGROUND:Despite their widespread use in this population, data on the pharmacodynamic (PD) properties of the insulin analogs detemir and glargine in severely obese patients with type 2 diabetes are lacking.
Stefan Bilz +5 more
doaj +1 more source
Molecular Pharmaceutics, 2019 Insulin detemir is a lipidated insulin analogue that obtains a half-life extension by oligomerization and reversible binding to human serum albumin. In the present study, the complex between a detemir hexamer and albumin is investigated by an integrative
L. A. Ryberg +4 more
semanticscholar +1 more source
Endocrinology and Metabolism, 2020 Background This study was conducted to compare glycaemic control with insulin detemir administered according to two titration algorithms (3-0-3 and 2-4-6-8) after 20 weeks of treatment in subjects with type 2 diabetes mellitus inadequately controlled on ...
H. Yu +7 more
semanticscholar +1 more source
Minimizing hypoglycemia while maintaining glycemic control in diabetes [PDF]
, 2008 In the accompanying Perspective, Cryer identifies a number of different areas where therapeutic interventions have the potential to reduce hypoglycemia without compromising glycemic control.
Heller, S.
core +3 more sources
Diabetic Medicine, Volume 43, Issue 2, February 2026.Abstract Aim Type 2 diabetes (T2D) in pregnancy is increasingly common and associated with suboptimal outcomes for these women and their children. We aimed to synthesize observational evidence on associations of modifiable preconception, pregnancy and postpartum risk factors with perinatal outcomes among women with pregestational T2D.
Danielle Schoenaker +11 more
wiley +1 more source